Fulton Breakefield Broenniman’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-7,123
Closed -$200K 214
2026
Q1
$200K Sell
7,123
-950
-12% -$25.3K 0.01% 196
2025
Q4
$201K Sell
8,073
-488
-6% -$12.3K 0.01% 199
2025
Q3
$218K Sell
8,561
-1,078
-11% -$26.6K 0.01% 189
2025
Q2
$234K Sell
9,639
-700
-7% -$16.3K 0.02% 174
2025
Q1
$262K Buy
10,339
+1,350
+15% +$35.3K 0.02% 151
2024
Q4
$238K Hold
8,989
0.02% 166
2024
Q3
$260K Sell
8,989
-113
-1% -$3.3K 0.02% 154
2024
Q2
$255K Sell
9,102
-3,481
-28% -$95.8K 0.02% 160
2024
Q1
$349K Buy
12,583
+1,232
+11% +$34.2K 0.03% 135
2023
Q4
$327K Sell
11,351
-78
-0.7% -$2.36K 0.03% 133
2023
Q3
$379K Sell
11,429
-824
-7% -$29.1K 0.03% 124
2023
Q2
$449K Sell
12,253
-689
-5% -$26.8K 0.04% 117
2023
Q1
$528K Sell
12,942
-150,820
-92% -$6.51M 0.05% 110
2022
Q4
$8.39M Buy
163,762
+411
+0.3% +$19.7K 0.74% 51
2022
Q3
$7.15M Sell
163,351
-1,227
-0.7% -$59.6K 0.67% 54
2022
Q2
$8.63M Sell
164,578
-4,830
-3% -$246K 0.75% 50
2022
Q1
$8.77M Buy
169,408
+647
+0.4% +$33.6K 0.77% 48
2021
Q4
$9.96M Buy
168,761
+1,472
+0.9% +$72.9K 0.74% 52
2021
Q3
$7.2M Sell
167,289
-3,908
-2% -$173K 0.62% 54
2021
Q2
$6.7M Sell
171,197
-141,285
-45% -$5.49M 0.57% 54
2021
Q1
$11.3M Buy
312,482
+41,663
+15% +$1.48M 1.05% 45
2020
Q4
$9.97M Sell
270,819
-60,197
-18% -$2.21M 1.19% 39
2020
Q3
$11.5M Sell
331,016
-3,662
-1% -$128K 1.3% 35
2020
Q2
$10.4M Buy
334,678
+3,261
+1% +$111K 1.26% 38
2020
Q1
$10.3M Sell
331,417
-3,318
-1% -$113K 1.53% 27
2019
Q4
$12.4M Buy
334,735
+9,361
+3% +$333K 1.45% 26
2019
Q3
$11.1M Buy
325,374
+8,026
+3% +$292K 1.41% 28
2019
Q2
$13M Buy
317,348
+2,389
+0.8% +$94.9K 2.06% 18
2019
Q1
$12.7M Buy
314,959
+706
+0.2% +$28.3K 2.06% 16
2018
Q4
$13M Buy
314,253
+927
+0.3% +$38.5K 2.3% 7
2018
Q3
$13.1M Sell
313,326
-2,304
-0.7% -$88.7K 2.04% 13
2018
Q2
$10.9M Buy
315,630
+114
+0% +$3.9K 1.74% 19
2018
Q1
$10.6M Sell
315,516
-5,225
-2% -$180K 1.84% 16
2017
Q4
$11M Buy
320,741
+870
+0.3% +$29.7K 1.85% 17
2017
Q3
$10.8M Sell
319,871
-9,129
-3% -$293K 1.89% 11
2017
Q2
$10.5M Buy
329,000
+16
+0% +$505 1.87% 13
2017
Q1
$10.7M Buy
328,984
+2,639
+0.8% +$83.2K 1.98% 11
2016
Q4
$10.1M Buy
326,345
+2,674
+0.8% +$81.6K 1.99% 12
2016
Q3
$10.4M Buy
323,671
+695
+0.2% +$23.2K 2.11% 6
2016
Q2
$10.8M Buy
322,976
+1,823
+0.6% +$58.2K 2.2% 5
2016
Q1
$9.03M Sell
321,153
-655
-0.2% -$18.7K 1.98% 11
2015
Q4
$9.86M Buy
321,808
+23,266
+8% +$732K 2.18% 5
2015
Q3
$8.9M Buy
298,542
+2,625
+0.9% +$84.2K 2.1% 4
2015
Q2
$9.41M Buy
295,917
+150
+0.1% +$4.89K 2.06% 2
2015
Q1
$9.76M Buy
295,767
+4,785
+2% +$152K 2.17% 2
2014
Q4
$8.6M Buy
290,982
+5,042
+2% +$145K 1.88% 9
2014
Q3
$8.02M Buy
285,940
+2,596
+0.9% +$72.9K 1.88% 7
2014
Q2
$7.98M Sell
283,344
-1,076
-0.4% -$30.7K 1.93% 5
2014
Q1
$8.67M Buy
284,420
+6,622
+2% +$197K 2.23% 1
2013
Q4
$8.07M Sell
277,798
-1,494
-0.5% -$43.5K 2.13% 3
2013
Q3
$7.61M Buy
279,292
+10,838
+4% +$295K 2.05% 1
2013
Q2
$7.13M Buy
+268,454
New +$7.42M 2.09% 1

Other funds holding PFE

Fulton Breakefield Broenniman's PFE Position: Q2 2026 in Review

Fulton Breakefield Broenniman sold out of Pfizer (PFE) in Q2 2026, closing a stake of 7,123 shares — an estimated $200K sold.

Fulton Breakefield Broenniman first reported a position in PFE in Q2 2013 and held it in 52 quarters. The position peaked at $13.1M in Q3 2018. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Fulton Breakefield Broenniman reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • Fulton Breakefield Broenniman sold 7,123 Pfizer shares in Q2 2026, an estimated $200K.
  • Fulton Breakefield Broenniman first reported a position in Pfizer in Q2 2013 and held it in 52 quarters.
  • Fulton Breakefield Broenniman's Pfizer position peaked at $13.1M in Q3 2018.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Fulton Breakefield Broenniman's 13F filing for Q2 2026, filed 3 Aug 2026.